(Q46657425)

24 December 2017

title

Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus (English)

1 reference

24 December 2017

0 references

0 references

1 reference

Carter AM

1

1 reference

24 December 2017

Bennett CE

series ordinal

2

1 reference

24 December 2017

Bostock JA

series ordinal

3

1 reference

24 December 2017

Grant PJ

series ordinal

4

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

published in

Diabetic Medicine

1 reference

24 December 2017

volume

22

1 reference

24 December 2017

issue

9

1 reference

24 December 2017

page(s)

1282-1284

1 reference

24 December 2017

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Association of serum C3 levels with the risk of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01632.X

10.1111/J.1464-5491.2005.01632.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017